Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Phase 2 Recruiting

105 enrolled

Tumor-Agnostic

Neoplasms

NCT06413706 2026-03-24

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Phase 2 Active not recruiting

45 enrolled

CNS

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03310879 2025-09-02

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

Phase 2 Recruiting

38 enrolled

Tumor-Agnostic

Neoplasms

NCT04534283 2024-08-07

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Phase 2 Terminated

16 enrolled 11 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03339843 2024-03-15

MiMe-A

Phase 2 Completed

85 enrolled

GastrointestinalGenitourinaryGynecologic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasms, Urologic Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

TAPUR

CAMPFIRE

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

I-SPY

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

MiMe-A

DRUP